Pfizer’s revenues are down 6% for the third quarter of 2025, according to an earnings statement. The percentage is the equivalent of $1 billion.
“Third-quarter 2025 revenues totaled $16.7 billion, a decrease of $1.0 billion, or 6%, compared to the prior-year quarter, reflecting an operational decrease of $1.3 billion, or 7%, and a favorable impact of foreign exchange of $203 million,” the report states. “The operational decrease was primarily driven by a year-over-year decline in COVID-19 product revenues largely due to lower infection rates impacting Paxlovid demand as well as a narrower vaccine recommendation for COVID-19 in the U.S. that reduced the eligible population for Comirnaty.”
The Comirnaty vaccine, down 20% operationally, reflects a “a narrower recommendation for vaccination in the U.S. as well as delayed approval of the new variant vaccine; partially offset by a lower returns provision and higher market share in the U.S., as well as higher contractual deliveries in certain international markets,” Pfizer added.
Similarly, sales of Paxlovid, a treatment for COVID-19, is down 55% due to “lower COVID-19 infections across U.S. and international markets and lower international government purchases.”
In October, the Centers for Disease Control and Prevention (CDC) updated its vaccine guidance to allow for individual decision-making and informed consent.
Acting Director of the CDC and Deputy Secretary of Health and Human Services Jim O’Neill said at the time that the agency’s “2022 blanket recommendation for perpetual COVID-19 boosters deterred health care providers from talking about the risks and benefits of vaccination for the individual patient or parent.”
